Table 3.

Risk of incident atherosclerotic and congestive heart failure events among participants without a history of congestive heart failure (n=3487) or atherosclerotic disease (n=2681) by baseline levels of FGF-23

VariableFGF-23
<96.0 RU/ml96.0–145.4 RU/ml145.5–238.9 RU/ml≥239.0 RU/mlContinuous per Doublinga
Atherosclerotic events
 Events (n)25223237
 Incidence per 1000 person-years8.48.614.620.4
 HR (95% CI)
  UnadjustedbReference1.03 (0.64 to 1.66)1.73 (1.04 to 2.89)2.42 (1.76 to 3.34)1.34 (1.22 to 1.47)
  Adjusted for demographic variables/kidney function cReference0.93 (0.53 to 1.62)1.39 (0.67 to 2.89)2.01 (1.12 to 3.63)1.27 (1.05 to 1.54)
  Adjusted for traditional risk factors dReference0.92 (0.51 to 1.64)1.23 (0.63 to 2.41)1.66 (0.82 to 3.38)1.24 (0.96 to 1.60)
  Adjusted for nontraditional risk factorseReference0.88 (0.47 to 1.65)1.26 (0.58 to 2.73)1.69 (0.68 to 4.18)1.25 (0.92 to 1.69)
Congestive heart failure hospitalization
 Events (n)253170104
 Incidence per 1000 person-years6.89.323.643.5
 HR (95% CI)
  UnadjustedbReference1.37 (0.85 to 2.21)3.48 (2.16 to 5.59)6.40 (4.37 to 9.38)1.74 (1.58 to 1.92)
  Adjusted for demographic variables/kidney functioncReference1.01 (0.62 to 1.65)1.83 (1.00 to 3.33)2.94 (2.01 to 4.30)1.50 (1.36 to 1.66)
  Adjusted for traditional risk factorsdReference1.09 (0.60 to 1.97)1.73 (1.04 to 2.86)2.36 (1.63 to 3.41)1.47 (1.27 to 1.69)
  Adjusted for nontraditional risk factorseReference1.09 (0.63 to 1.87)1.66 (1.00 to 2.75)2.16 (1.49 to 3.13)1.41 (1.21 to 1.64)
  • a Risk per 1-unit change in log2(FGF-23).

  • b All models are clustered by clinical center.

  • c Adjusted for age, sex, race/ethnicity, income, eGFR, and urine albumin-to-creatinine ratio.

  • d Adjusted for covariates in the demographic and kidney function adjusted model, plus history of hypertension; hypercholesterolemia; history of atherosclerotic cardiovascular disease; history of congestive heart failure; diabetes; control of BP to <140/90 mmHg; hemoglobin A1c; smoking status; body mass index; waist circumference; serum triglycerides; LDL cholesterol; use of antiplatelet medications, angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers, β-blockers, statins, and loop diuretics; and the number of prescribed classes of BP medications.

  • e Adjusted for covariates in the traditional risk factor– and medication-adjusted model, plus serum phosphate, calcium, albumin, C-reactive protein, PTH, and hemoglobin.